SD ELAD Biotechnology Co. Ltd., is developing the world first human liver cell-based therapy that provides metabolic support for patients with severe liver failure, the Extracorporeal Liver Assist Device (ELAD®). ELAD bioartificial liver therapy is based on the human hepatoblastoma-derived, immortalized cell line C3A, cultured in hollow fiber cartridges. The cells are the key in supporting a liver failure patient by processing liver toxins and synthesizing human liver proteins.